

Screening for Substance Use Disorder in the Oncology/Hematology Patient

Antonia Corrigan, MSN, ANP-C, ACHPN

References

American Addiction Centers. CAGE Questionnaire (4 Questions to Screen for Alcoholism). November 19, 2021. Accessed July 27, 2023.

<https://americanaddictioncenters.org/alcoholism-treatment/cage-questionnaire-assessment>

American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition*. 2013.

Arthur JA. Urine drug testing in cancer pain management. *Oncologist*. 2020;25(2):99-104.

Boonyathee S, Nagaviroj K, Anothaisintawee T. The accuracy of the Edmonton Symptom Assessment System for the assessment of depression in patients with cancer: a systematic review and meta-analysis. *Am J Hosp Palliat Care*. 2018;35(4):731-739.

Brandeis University. The Heller School for Social Policy and Management. Technical Assistance Guide: History of Prescription Drug Monitoring Programs. March 2018. Accessed August 12, 2023.

https://www.pdmpassist.org/pdf/PDMP_admin/TAG_History_PDMPs_final_20180314.pdf

Cheatle MD, Compton PA, Dhingra L, Wasser TE, O'Brien CP. Development of the revised Opioid Risk Tool to predict opioid use disorder in patients with chronic nonmalignant pain. *J Pain*. 2019;20(7):842-851.

Choflet A, Hoofring L, Cheng Z, Katulis L, Narang A, Appling S. Substance use screening protocol: implementation of a system for patients with cancer. *Clin J Oncol Nurs*. 2020;24(5):554-560.

Dalal S, Bruera E. Pain management for patients with advanced cancer in the opioid epidemic era. *Am Soc Clin Oncol Educ Book*. 2019;39:24-35.

Dennis BB, Bawor M, Naji L, Chan CK, Varenbut J, Paul J, Varenbut M, Daiter J, Plater C, Pare G, Marsh DC, Worster A, Desai D, Thabane L, Samaan Z. Impact of chronic pain on treatment prognosis for patients with opioid use disorder: a systematic review and meta-analysis. *Subst Abuse*. 2015;9:59-80.

Edwards T, Foster T, Brant JM. Managing cancer pain in patients with opioid and substance use disorders. *Semin Oncol Nurs*. 2019;35(3):279-283.

Hui D, Bruera E. The Edmonton Symptom Assessment System 25 years later: past, present, and future developments. *J Pain Symptom Manage*. 2017;53(3):630-643.

LabCorp. ToxAssure Flex 23, Urine. 2021. Accessed August 12, 2023. <https://www.labcorp.com/tests/912335/toxassure-flex-23-urine>

Le TT, Fleming SP, Kuzucan A, Dizik A, Simoni-Wastila L. Query mandates in prescription drug monitoring programs reduce opioid use among commercially insured patients with cancer. *J Am Pharm Assoc (2003)*. 2022;62(1):363-369.

Moussas GI, Papadopoulou AG. Substance abuse and cancer. *Psychiatriki*. 2017;28(3):234-241.

Raouf M, Bettinger JJ, Fudin J. A practical guide to urine drug monitoring. *Fed Pract*. 2018;35(4):38-44.

Saint Louis University. Screener and Opioid Assessment for Patients with Pain (SOAPP)[®] Version 1.0-SF. 2008. Accessed August 12, 2023. <https://www.slu.edu/medicine/family-medicine/pdfs/soapp.pdf>

Substance Abuse and Mental Health Services Administration. Mental Health and Substance Use Disorders. 2023. Accessed August 11, 2023. <https://www.samhsa.gov/find-help/disorders>

The Calculator. Opioid Risk Tool Calculator. September 30, 2015. Accessed August 12, 2023. <https://www.thecalculator.co/health/Opioid-Risk-Tool-Calculator-869.html>
Williams N. The CAGE questionnaire. *Occup Med (Lond)*. 2014;64(6):473-474.

Yennurajalingam S, Arthur J, Reddy S, Edwards T, Lu Z, Rozman de Moraes A, Wilson SM, Erdogan E, Joy MP, Ethridge SD, Kuriakose L, Malik JS, Najera JM, Rashid S, Qian Y, Kubiak MJ, Nguyen K, PharmD, Wu J, Hui D, Bruera E. Frequency of and factors associated with nonmedical opioid use behavior among patients with cancer receiving opioids for cancer pain. *JAMA Oncol*. 2021;7(3):404-411.